Equities research analysts predict that Supernus Pharmaceuticals Inc (NASDAQ:SUPN) will report sales of $108.92 million for the current quarter, Zacks reports. Four analysts have provided estimates for Supernus Pharmaceuticals’ earnings, with the highest sales estimate coming in at $112.26 million and the lowest estimate coming in at $107.10 million. Supernus Pharmaceuticals reported sales of $99.54 million during the same quarter last year, which indicates a positive year-over-year growth rate of 9.4%. The firm is expected to announce its next quarterly earnings report on Tuesday, August 6th.
On average, analysts expect that Supernus Pharmaceuticals will report full year sales of $439.18 million for the current fiscal year, with estimates ranging from $428.00 million to $448.46 million. For the next year, analysts expect that the company will report sales of $516.10 million, with estimates ranging from $505.79 million to $526.01 million. Zacks’ sales calculations are an average based on a survey of research firms that follow Supernus Pharmaceuticals.
Supernus Pharmaceuticals (NASDAQ:SUPN) last issued its earnings results on Tuesday, May 7th. The specialty pharmaceutical company reported $0.34 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.44 by ($0.10). Supernus Pharmaceuticals had a return on equity of 23.60% and a net margin of 25.49%. The firm had revenue of $85.50 million during the quarter, compared to the consensus estimate of $102.26 million. During the same quarter in the prior year, the business earned $0.49 earnings per share. Supernus Pharmaceuticals’s revenue for the quarter was down 5.4% on a year-over-year basis.
A number of hedge funds and other institutional investors have recently added to or reduced their stakes in SUPN. Financial Gravity Wealth Inc. purchased a new stake in shares of Supernus Pharmaceuticals during the 1st quarter valued at $44,000. Advisor Group Inc. increased its holdings in Supernus Pharmaceuticals by 17.2% in the 4th quarter. Advisor Group Inc. now owns 2,082 shares of the specialty pharmaceutical company’s stock worth $69,000 after acquiring an additional 306 shares during the last quarter. Bremer Bank National Association purchased a new stake in Supernus Pharmaceuticals in the 1st quarter worth about $94,000. Huntington National Bank increased its holdings in Supernus Pharmaceuticals by 881.4% in the 1st quarter. Huntington National Bank now owns 4,485 shares of the specialty pharmaceutical company’s stock worth $157,000 after acquiring an additional 4,028 shares during the last quarter. Finally, Adams Diversified Equity Fund Inc. purchased a new stake in Supernus Pharmaceuticals in the 1st quarter worth about $200,000. 99.29% of the stock is owned by institutional investors and hedge funds.
Shares of SUPN traded up $0.04 during trading hours on Wednesday, reaching $32.25. The stock had a trading volume of 8,864 shares, compared to its average volume of 556,461. Supernus Pharmaceuticals has a 12 month low of $29.60 and a 12 month high of $56.40. The stock’s 50-day moving average is $31.76. The company has a debt-to-equity ratio of 0.75, a current ratio of 2.77 and a quick ratio of 2.59. The firm has a market cap of $1.69 billion, a P/E ratio of 15.78, a price-to-earnings-growth ratio of 1.10 and a beta of 1.61.
About Supernus Pharmaceuticals
Supernus Pharmaceuticals, Inc, a pharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system diseases in the United States. It offers Oxtellar XR, an extended-release oxcarbazepine for use in the treatment of epilepsy; and Trokendi XR, an extended-release topiramate, which is used for the treatment of epilepsy and migraine.
Recommended Story: What moving averages are used to define a golden cross?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Supernus Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Supernus Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.